Acute effects of acephate and methamidophos and interleukin-1 on corticotropin-releasing factor (CRF) synthesis in and release from the hypothalamus in vitro.
Acute effects of Ace, Meth and IL-1 on AChE activity, ACh and CRF mRNA levels in, and CRF-release from the hypothalamus were studied in vitro. The hypothalamus samples were dissected from the rat brain and were incubated in vitro with IL-1, Ace or Meth in the presence or absence of Dex, Atrop, PTL, PROP and GABA. Ace and Meth, but not IL-1, inhibited AChE activity, while all three compounds; (1) increased ACh and CRF mRNA levels in and CRF release from; (2) activated the CRE promoter region of CRF-gene in: and (3) increased cFos binding to the AP-1 region of the CRF-gene in the hypothalamus. Dex suppressed the effects of IL-1, possibly by inducing the nGRE regulatory sites of the CRF-gene. Dex, however, did not modulate the effects of Ace and Meth on the hypothalamus, which may be attributed to the failure of Dex to modulate the CRF-gene's nGRE regulatory sites. Atrop caused 80-90% inhibition of the effects of IL-1, but caused only 50-65% inhibition of the effects of Ace or Meth on CRF mRNA levels in and CRF release from the hypothalamus. PTL did not affect, while PROP slightly attenuated the effects of IL-1 and the insecticides on the hypothalamus. GABA attenuated the effects of the insecticides but not the effects of IL-1 on the hypothalamus. This suggests that the IL-1-induced augmentation of CRF synthesis in and release from the hypothalamus is mediated through a cholinergic pathway, while the insecticide-induced augmentation of CRF synthesis in and release from the hypothalamus is mediated through the cholinergic and GABAergic pathways. The insecticides, but not IL-1, disrupt feedback regulation of CRF synthesis in and release from the hypothalamus.
Singh
A K
AK
Department of Veterinary Diagnostic Medicine, Minnesota Veterinary Diagnostic Laboratory, University of Minnesota, 1333 Gorter Avenue, St Paul, MN 55108, USA. singh@maroon.te.umn
D000109:Acetylcholine / Q000032:analysis; D000110:Acetylcholinesterase / Q000378:metabolism; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D003346:Corticotropin-Releasing Hormone / Q000096:biosynthesis* / Q000235:genetics / Q000378:metabolism*; D003907:Dexamethasone / Q000494:pharmacology; D024202:Electrophoretic Mobility Shift Assay; D007031:Hypothalamus / Q000737:chemistry / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism*; D066298:In Vitro Techniques; D007375:Interleukin-1 / Q000494:pharmacology*; D007700:Kinetics; D008297:Male; D009946:Organothiophosphorus Compounds / Q000032:analysis / Q000494:pharmacology*; D010646:Phentolamine / Q000494:pharmacology; D063088:Phosphoramides; D011433:Propranolol / Q000494:pharmacology; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology
D007375:Interleukin-1; D009946:Organothiophosphorus Compounds; D063088:Phosphoramides; D012333:RNA, Messenger; C001969:acephate; D005680:gamma-Aminobutyric Acid; D001285:Atropine; D003907:Dexamethasone; C014655:methamidophos; D003346:Corticotropin-Releasing Hormone; D011433:Propranolol; D000110:Acetylcholinesterase; D000109:Acetylcholine; D010646:Phentolamine